*Given the hierarchical nature of the statistical testing, the p-values for the primary and key secondary endpoints should be considered significant, whereas all other p-values
†The treatment effect on stroke was driven by a reduction in risk of ischaemic stroke; there was no effect on haemorrhagic or undetermined stroke.
‡Assessment of time to hospitalisation for UA was ad-hoc.
§In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
║25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62–0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2–5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CI = Confidence interval; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS =
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; FOURIER = Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk; HR = Hazard ratio; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/
kexin type 9; RRR = Relative risk reduction; UA = Unstable angina.
- Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
- Sabatine MS, et al. N Engl J Med. 2017;376:1713-22.
- Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.